*Promoted by Sideways Frequency  

CYBN is in “Rocket Mode” 🚀After Receiving 

FDA Breakthrough Therapy Designation

Buckle up, team. We have a very busy Friday ahead of us!

Today, there is a major options expiration happening today, which is likely to cause considerable volatility in the markets.

While the major indexes have been swinging back and forth, they really haven’t made any ground lately.  

In fact, would you believe that after all of the big days the market has seen lately, it is still trading at the same point it was a month ago?

It has been very frustrating for most options traders who are trying to ride moves more than a day at a time.

One spot that continues to find life is the small-cap sector, and especially biotechs. 🧬

To wrap up our week, I have found an extremely interesting new idea.

It just came on my radar a couple of weeks ago when I was scanning stocks and found one that was making a perfect Gamma Trigger breakout.

Since I know so many people love super-low priced stocks, I think you’ll find this one especially interesting – it’s less than 50 cents right now.

I want you to pull up Cybin (CYBN) right now and start to look at it closely.

In the chart below, you can see that perfect signal we saw right before it snapped off a 70% move to the upside…

Honestly, I was pretty ticked off for spotting this before it happened, but not pulling the trigger on it.

Well, I have been watching this one really closely and waiting for what could be the next spot to get involved.

I think TODAY is the perfect time to get CYBN on your radar.

If you can see in the chart, after a pullback for a few days, CYBN is within a hair of trading back above the 20-hour line.

The purple candles are signaling a potential trend change is around the corner.  If that happens and they switch to blue, we could get a “GO” signal today.

You know what that means… We would have another perfect Gamma Trigger signal!

It is extremely important to keep a close eye on CYBN today.  

If this is indeed the day it decides to resume the uptrend, you will not want to be sitting on the sidelines watching it unfold… like I was last time!

While the chart setup is amazing right now, I think you’ll really like learning what CYBN does.

It is not your typical tiny stock.

CYBN is a leader in developing psychedelics-based therapies for mental illnesses including major depressive disorder (MDD), generalized anxiety disorder (GAD), and alcohol use disorder (AUD).

CYBN is a clinical-stage biopharmaceutical company that takes its name from psilocybin — the active ingredient in “magic mushrooms.” 🍄

The company has been featured in the likes of Time, Forbes, Business Insider and many other prominent media.

And if there was any doubt about CYBN’s prominent standing in this space, Wednesday’s announcement of a “Breakthrough Therapy Designation” (BTD) for its novel CYB003 molecule should clear that up.

According to the FDA, which grants that designation, it is “designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.”

It not only grants the recipient all the benefits of “Fast Track,” it also includes “more intensive FDA guidance and discussion of the CYB003 development program, including planned clinical trials and plans for expediting the manufacturing development strategy.”

“CYB003 is eligible for Priority Review and Accelerated Approval,” the company added.

CYBN also said this is the “first known BTD granted by the FDA for an adjunctive psychedelic-based therapy for the treatment of Major Depressive Disorder.”

This landmark achievement comes after the company completed its Phase II clinical trial of CYB003 — a proprietary molecule derived from psilocybin — for MDD.

The trial’s results were extraordinary…

Researchers found that, four months after dosing, “60% of patients receiving 12mg and 75% of patients receiving 16mg of CYB003 achieved remission from depression symptoms.”

This chart plots the results in terms of scores on the Montgomery-Asberg Depression Rating Scale (“MADRS”). For reference, the test is scored from 0–60 and the mean baseline scores in the group receiving CYB003 were 31.4 to 33.7.

As you can see, even at D126 (day 126, or four months after dosing), recipients had dramatic reductions in depression scores. (A score of 0–6 is considered normal; 7–19 is mild depression).

Better yet, when compared with existing MDD treatments, including the popular SSRIs, CYB003 trounced the competition after just a single dose:

I didn’t realize this, but more than 43 million Americans take antidepressants, and more than 70% of them are treated with SSRIs.

If these results pan out in the Phase III trial the company plans to begin in Q2 of this year, this could be a very big deal.

On top of CYB003, the company is also developing a DMT–derived compound for treatment of generalized anxiety disorder, and it expects to begin the Phase II trial for that in the next few weeks with preliminary results expected before the end of the year.

I was also very impressed with CYBN’s management team, which has brought dozens of drugs to market, including widely used drugs such as Allegra, Sabril, Anzemet, Latuda, Vaniqa, and esketamine. The scientific team has more than 300 combined peer-reviewed publications between them.

I strongly encourage you to do your own due diligence, and of course, always approach your trading in a responsible manner. Never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: CYBN has overcome incredible odds to reach the milestones they achieved. While there is a lot of work to go before commercialization, CYBN is laser-focused on becoming a leader in this niche biotech sector.  

This is one idea that you really need to dig into this morning.  The potential here is insane!

To Your Success,

Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!

*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.



*PAID ADVERTISEMENT. Raging Bull has currently been paid twenty thousand dollars from Sideways Frequency, who was compensated by a third party not affiliated with the Company for advertising Cybin Inc for a one-day marketing program commencing on march 15, 2024. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Cybin Inc, increased trading volume, and possibly an increased share price of Cybin Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Cybin Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.